This article was originally published in The Tan Sheet
FDA revises its estimate for annual mandatory adverse event reports related to dietary supplement products to 856 from 960, based on the 214 AERs it received between Jan. 1 and April 15, according to a Sept. 15 Federal Register notice. In a separate same-day notice, FDA announces it received no comments following an October 2007 notice about information collection provisions for nonprescription drug AERs. The agency's estimate for annual serious OTC AERs will remain at 12,500 from approximately 50 respondents
You may also be interested in...
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.